DDInter740 DDInter1400
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Pazopanib
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Pazopanib
Flecainide {u} (Compound) downregulates {v} (Gene) SHB
SHB {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Flecainide {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Pazopanib
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Donepezil
Donepezil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Pazopanib
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is regulated by {v} (Gene) RIOK2
RIOK2 {u} (Gene) is bound by {v} (Compound) Pazopanib
Flecainide {u} (Compound) upregulates {v} (Gene) EIF4EBP1
EIF4EBP1 {u} (Gene) is associated with {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is treated by {v} (Compound) Pazopanib
Flecainide {u} (Compound) downregulates {v} (Gene) SHB
SHB {u} (Gene) interacts with {v} (Gene) FGFR1
FGFR1 {u} (Gene) is bound by {v} (Compound) Pazopanib
Flecainide {u} (Compound) downregulates {v} (Gene) EXT1
EXT1 {u} (Gene) is regulated by {v} (Gene) SH2B3
SH2B3 {u} (Gene) is bound by {v} (Compound) Pazopanib
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pazopanib (Compound)
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Pazopanib (Compound)
Flecainide (Compound) downregulates SHB (Gene) and SHB (Gene) is downregulated by Pazopanib (Compound)
Flecainide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Donepezil (Compound) and Donepezil may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is regulated by RIOK2 (Gene) and RIOK2 (Gene) is bound by Pazopanib (Compound)
Flecainide (Compound) upregulates EIF4EBP1 (Gene) and EIF4EBP1 (Gene) is associated with kidney cancer (Disease) and kidney cancer (Disease) is treated by Pazopanib (Compound)
Flecainide (Compound) downregulates SHB (Gene) and SHB (Gene) interacts with FGFR1 (Gene) and FGFR1 (Gene) is bound by Pazopanib (Compound)
Flecainide (Compound) downregulates EXT1 (Gene) and EXT1 (Gene) is regulated by SH2B3 (Gene) and SH2B3 (Gene) is bound by Pazopanib (Compound)